Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.

13 In that same analysis, we observed an encouraging trend towards better survival outcomes associated with such a molecular downstaging. 13 In a small study from Hilal et al., 28 NET induced a reduction in ER and PgR, consistent with our findings, though a slight increase in molecular risk of relapse, as detected with the 21-gene Oncotype DX® assay, was observed.

also in 141 other papers

9 , 26 In our study, patients with HR+/HER2-low and HR+/HER2-0 disease seemed to experience comparable long-term outcomes, with marginal differences that did not reach statistical significance.

also in 45,344 other papers